GrandeLASH Lawsuits: Beauty Quest Ends in Legal Battle

Grande Cosmetics is currently facing a class action lawsuit over its hair growth serums.

Grande Cosmetics is currently facing a class action lawsuit over its hair growth serums. The GrandeLASH lawsuit alleges that the company mislabeled its lash, brow, and hair growth serums as cosmetics, whereas they contain an active drug ingredient, isopropyl cloprostenate (ICP), which should only be used under a physician’s supervision due to the risk of serious side effects including eye damage.

Alicia Grande, who has always had a fascination with beauty, launched Grande Cosmetics in 2008 with the ground-breaking GrandeLASH-MD Lash Enhancing Serum.

Grande Cosmetics agrees to pay $6.25 million to settle allegations in a false advertising class action complaint that was filed by Brenda Nixon in federal court in New Jersey in November 2022. The company has also agreed to update the text on its packaging and its website. However, Grande maintains her denial of the charges in the complaint and does not acknowledge any wrongdoing.

The class action lawsuit claims that Grande neglected to inform customers that isopropyl cloprostenate, a medication used to treat glaucoma, is an ingredient in its GrandeLASH-MD, GrandeBROW, and GrandeHAIR products. It is said that isopropyl cloprostenate might result in serious side effects, including irritation of the eyes, which Grande Cosmetics failed to state.

The plaintiffs argue that Grande Cosmetics knew the serums could cause damage but continued to sell them without adequate warnings or obtaining necessary regulatory approvals. The cosmetic lawsuit claims that the company sold hundreds of thousands of units of these serums in California alone, priced $65-$125 each, while aware of consumer complaints and injuries. The plaintiffs are seeking class certification, restitution, damages, enjoinment, legal fees, costs, interest, and a jury trial.

This lawsuit raises significant concerns regarding consumer safety and the regulatory classification of products that contain drug ingredients but are marketed as cosmetics. It also highlights the importance of transparency and adherence to regulatory requirements in product marketing and sales.

As the lawsuits progresses, it will be crucial to monitor the outcomes and the potential impact on industry practices. This case could prompt a reevaluation of regulatory standards and enforcement practices to ensure that products with drug-like effects undergo the necessary scrutiny and approval process. It also serves as a reminder to companies about the importance of transparency, ethical marketing, and the prioritization of consumer safety over profit.

The class action lawsuit against Grande Cosmetics represents a pivotal moment for the beauty industry and regulatory bodies. It calls into question the responsibility of companies to accurately represent their products and the role of regulations in safeguarding public health. As consumers become increasingly aware of the ingredients in their beauty products, the industry must adapt to ensure safety, compliance, and trust. This case may well set a precedent for how similar issues are handled in the future, emphasizing the importance of integrity in product development and marketing.